CA
IMVT icon

Clearstead Advisors’s Immunovant IMVT Stock Holding History

Clearstead Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116 Buy
+3
New +$91 ﹤0.01% 3336

Other funds holding IMVT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Clearstead Advisors's IMVT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Immunovant (IMVT) in Q2 2026: 3 shares worth $116. The stake represents ﹤0.01% of the portfolio and ranks #3336 among its holdings.

73 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Clearstead Advisors held 3 shares of Immunovant worth $116 as of Q2 2026.
  • Immunovant was a new Clearstead Advisors position in Q2 2026.
  • Immunovant made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3336 holding.
  • 73 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.